Up-regulation of a HOXA-PBX3 homeobox-gene signature following down-regulation of miR-181 is associated with adverse prognosis in patients with cytogenetically abnormal AML

Blood

Volumn 119, Issue 10, 2012, Pages 2314-2324

  Li, Zejuan ^a   Huang, Hao ^a   Li, Yuanyuan ^a   Jiang, Xi ^a   Chen, Ping ^a   Arnovitz, Stephen ^a   Radmacher, Michael D ^b   Maharry, Kati ^b   Elkahloun, Abdel ^c   Yang, Xinan ^d   He, Chunjiang ^a   He, Miao ^a   Zhang, Zhiyu ^e   Dohner, Konstanze ^f   Neilly, Mary Beth ^a   Price, Colles ^a   Lussier, Yves A ^d   Zhang, Yanming ^a   Larson, Richard A ^a   Le Beau, Michelle M ^a   Caligiuri, Michael A ^b   Bullinger, Lars ^f   Valk, Peter J M ^g   Delwel, Ruud ^g   Lowenberg, Bob ^g   Liu, Paul P ^c   Marcucci, Guido ^b   Bloomfield, Clara D ^b   Rowley, Janet D ^a   Chen, Jianjun ^a   more..

^a SECTION OF HEMATOLOGY ONCOLOGY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

^e UNIVERSITY OF CHICAGO   (United States)

^f UNIVERSITY OF ULM   (Germany)

^g ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; MICRORNA 181; MICRORNA 181A; MICRORNA 181B; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; APOPTOSIS; ARTICLE; CANCER PATIENT; CELL PROLIFERATION; CELL VIABILITY; CHILD; CYTOGENETICS; DOWN REGULATION; FEMALE; GENE EXPRESSION; HOMEOBOX; HOXA GENE; HOXA11 GENE; HOXA7 GENE; HOXA9 GENE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL; LEUKEMOGENESIS; MAJOR CLINICAL STUDY; MALE; MULTIGENE FAMILY; NUCLEOTIDE SEQUENCE; OVERALL SURVIVAL; PBX3 GENE; PRIORITY JOURNAL; PROGNOSIS; UPREGULATION; VALIDATION PROCESS;

EID: 84863269138     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-10-386235     Document Type: Article

References (50)

1. He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet. 2004; 5(7):522-531. (Pubitemid 38868508)
2. Esquela-Kerscher A, Slack FJ. Oncomirs: microRNAs with a role in cancer. Nat Rev Cancer. 2006;6(4):259-269.
3. He L, Thomson JM, Hemann MT, et al. A microRNA polycistron as a potential human oncogene. Nature. 2005;435(7043):828-833. (Pubitemid 40839734)
4. Chen J, Odenike O, Rowley JD. Leukaemogenesis: more than mutant genes. Nat Rev Cancer. 2010;10(1):23-36.
5. Marcucci G, Mrozek K, Radmacher MD, Garzon R, Bloomfield CD. The prognostic and functional role of microRNAs in acute myeloid leukemia. Blood. 2011;117(4):1121-1129.
6. Garzon R, Volinia S, Liu CG, et al. MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood. 2008; 111(6):3183-3189.
7. Marcucci G, Radmacher MD, Maharry K, et al. MicroRNA expression in cytogenetically normal acute myeloid leukemia. N Engl J Med. 2008; 358(18):1919-1928. (Pubitemid 351620112)
8. Marcucci G, Maharry K, Radmacher MD, et al. Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study. J Clin Oncol. 2008;26(31):5078-5087.
9. Schwind S, Maharry K, Radmacher MD, et al. Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol. 2010;28(36):5257-5264.
10. Chen CZ, Li L, Lodish HF, Bartel DP. MicroRNAs modulate hematopoietic lineage differentiation. Science. 2004;303(5654):83-86. (Pubitemid 38055775)
11. Li QJ, Chau J, Ebert PJ, et al. miR-181a is an intrinsic modulator of T cell sensitivity and selection. Cell. 2007;129(1):147-161. (Pubitemid 46507589)
12. Pekarsky Y, Cimmino A, Palamarchuk A, et al. Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181. Cancer Res. 2006;66(24):11590-11593. (Pubitemid 46094168)
13. Iliopoulos D, Jaeger SA, Hirsch HA, Bulyk ML, Struhl K. STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer. Mol Cell. 2010;39(4):493-506.
14. Wang B, Hsu SH, Majumder S, et al. TGFbeta-mediated upregulation of hepatic miR-181b promotes hepatocarcinogenesis by targeting TIMP3. Oncogene. 2010;29(12):1787-1797.
15. Sitwala KV, Dandekar MN, Hess JL. HOX proteins and leukemia. Int J Clin Exp Pathol. 2008; 1(6):461-474.
16. Shah N, Sukumar S. The Hox genes and their roles in oncogenesis. Nat Rev Cancer. 2010; 10(5):361-371.
17. Milech N, Kees UR, Watt PM. Novel alternative PBX3 isoforms in leukemia cells with distinct interaction specificities. Genes Chromosomes Cancer. 2001;32(3):275-280. (Pubitemid 32953981)
18. Thorsteinsdottir U, Kroon E, Jerome L, Blasi F, Sauvageau G. Defining roles for HOX and MEIS1 genes in induction of acute myeloid leukemia. Mol Cell Biol. 2001;21(1):224-234.
19. Armstrong SA, Staunton JE, Silverman LB, et al. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet. 2002;30(1):41-47.
20. Bullinger L, Dohner K, Bair E, et al. Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. N Engl J Med. 2004;350(16):1605-1616. (Pubitemid 38501163)
21. Zeisig BB, Milne T, Garcia-Cuellar MP, et al. Hoxa9 and Meis1 are key targets for MLL-ENL-mediated cellular immortalization. Mol Cell Biol. 2004;24(2):617-628. (Pubitemid 38057914)
22. Milne TA, Martin ME, Brock HW, Slany RK, Hess JL. Leukemogenic MLL fusion proteins bind across a broad region of the Hox a9 locus, promoting transcription and multiple histone modifications. Cancer Res. 2005;65(24):11367-11374. (Pubitemid 41821694)
23. Krivtsov AV, Twomey D, Feng Z, et al. Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature. 2006; 442(7104):818-822. (Pubitemid 44258912)
24. Faber J, Krivtsov AV, Stubbs MC, et al. HOXA9 is required for survival in human MLL-rearranged acute leukemias. Blood. 2009;113(11):2375-2385.
25. Li Z, Luo RT, Mi S, et al. Consistent deregulation of gene expression between human and murine MLL rearrangement leukemias. Cancer Res. 2009;69(3):1109-1116.
26. Slany RK. The molecular biology of mixed lineage leukemia. Haematologica. 2009;94(7):984-993.
27. Bach C, Buhl S, Mueller D, Garcia-Cuellar MP, Maethner E, Slany RK. Leukemogenic transformation by HOXA cluster genes. Blood. 2010; 115(14):2910-2918.
28. Kok CH, Brown AL, Ekert PG, D'Andrea RJ. Gene expression analysis reveals HOX gene upregulation in trisomy 8 AML. Leukemia. 2010; 24(6):1239-1243.
29. Golub TR, Slonim DK, Tamayo P, et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science. 1999;286(5439):531-537.
30. Drabkin HA, Parsy C, Ferguson K, et al. Quantitative HOX expression in chromosomally defined subsets of acute myelogenous leukemia. Leukemia. 2002;16(2):186-195. (Pubitemid 34145135)
31. Andreeff M, Ruvolo V, Gadgil S, et al. HOX expression patterns identify a common signature for favorable AML. Leukemia. 2008;22(11):2041-2047.
32. Wouters BJ, Lowenberg B, Erpelinck-Verschueren CA, van Putten WL, Valk PJ, Delwel R. Double CEBPAmutations, but not single CEBPAmutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome. Blood. 2009; 113(13):3088-3091.
33. Li Z, Lu J, Sun M, et al. Distinct microRNA expression profiles in acute myeloid leukemia with common translocations. Proc Natl Acad Sci U S A. 2008;105(40):15535-15540.
34. Mi S, Lu J, Sun M, et al. MicroRNA expression signatures accurately discriminate acute lymphoblastic leukemia from acute myeloid leukemia. Proc Natl Acad Sci U S A. 2007;104(50):19971-19976.
35. Radmacher MD, McShane LM, Simon R. A paradigm for class prediction using gene expression profiles. J Comput Biol. 2002;9(3):505-511. (Pubitemid 34920572)
36. Stouffer SA, Suchman EA, DeVinney LC, Star SA, Williams RMJ. Adjustment During Army Life. Princeton, NJ: Princeton University Press; 1949.
37. Hommel G. A stagewise rejective multiple test procedure based on a modified Bonferroni test. Biometrika. 1988;75(2):383-386.
38. Mi S, Li Z, Chen P, et al. Aberrant overexpression and function of the miR-17-92 cluster in MLL-rearranged acute leukemia. Proc Natl Acad Sci U S A. 2010;107(8):3710-3715.
39. Dohner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115(3):453-474.
40. Popovic R, Zeleznik-Le NJ. MLL: how complex does it get? J Cell Biochem. 2005;95(2):234-242. (Pubitemid 41420194)
41. Ayton PM, Cleary ML. Transformation of myeloid progenitors by MLL oncoproteins is dependent on Hoxa7 and Hoxa9. Genes Dev. 2003;17(18): 2298-2307. (Pubitemid 37128644)
42. Slany RK, Lavau C, Cleary ML. The oncogenic capacity of HRX-ENL requires the transcriptional transactivation activity of ENL and the DNA binding motifs of HRX. Mol Cell Biol. 1998;18(1):122-129. (Pubitemid 28021024)
43. So CW, Lin M, Ayton PM, Chen EH, Cleary ML. Dimerization contributes to oncogenic activation of MLL chimeras in acute leukemias. Cancer Cell. 2003;4(2):99-110. (Pubitemid 37040826)
44. Smith LL, Yeung J, Zeisig BB, et al. Functional crosstalk between Bmi1 and MLL/Hoxa9 axis in establishment of normal hematopoietic and leukemic stem cells. Cell Stem Cell. 2011;8(6):649-662.
45. Wong P, Iwasaki M, Somervaille TC, So CW, Cleary ML. Meis1 is an essential and rate-limiting regulator of MLL leukemia stem cell potential. Genes Dev. 2007;21(21):2762-2774. (Pubitemid 350070722)
46. Kota J, Chivukula RR, O'Donnell KA, et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell. 2009; 137(6):1005-1017.
47. Trang P, Wiggins JF, Daige CL, et al. Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice. Mol Ther. 2011;19(6):1116-1122.
48. Morgan R, Pirard PM, Shears L, Sohal J, Pettengell R, Pandha HS. Antagonism of HOX/PBX dimer formation blocks the in vivo proliferation of melanoma. Cancer Res. 2007;67(12): 5806-5813. (Pubitemid 46985014)
49. Plowright L, Harrington KJ, Pandha HS, Morgan R. HOX transcription factors are potential therapeutic targets in non-small-cell lung cancer (targeting HOX genes in lung cancer). Br J Cancer. 2009;100(3): 470-475.
50. Morgan R, Plowright L, Harrington KJ, Michael A, Pandha HS. Targeting HOX and PBX transcription factors in ovarian cancer. BMC Cancer. 2010; 10:89.